Literature DB >> 22710432

Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia.

Constance Baer1, Rainer Claus, Lukas P Frenzel, Manuela Zucknick, Yoon Jung Park, Lei Gu, Dieter Weichenhan, Martina Fischer, Christian Philipp Pallasch, Esther Herpel, Michael Rehli, John C Byrd, Clemens-Martin Wendtner, Christoph Plass.   

Abstract

Dysregulated microRNA (miRNA) expression contributes to the pathogenesis of hematopoietic malignancies, including chronic lymphocytic leukemia (CLL). However, an understanding of the mechanisms that cause aberrant miRNA transcriptional control is lacking. In this study, we comprehensively investigated the role and extent of miRNA epigenetic regulation in CLL. Genome-wide profiling conducted on 24 CLL and 10 healthy B cell samples revealed global DNA methylation patterns upstream of miRNA sequences that distinguished malignant from healthy cells and identified putative miRNA promoters. Integration of DNA methylation and miRNA promoter data led to the identification of 128 recurrent miRNA targets for aberrant promoter DNA methylation. DNA hypomethylation accounted for more than 60% of all aberrant promoter-associated DNA methylation in CLL, and promoter DNA hypomethylation was restricted to well-defined regions. Individual hyper- and hypomethylated promoters allowed discrimination of CLL samples from healthy controls. Promoter DNA methylation patterns were confirmed in an independent patient cohort, with 11 miRNAs consistently showing an inverse correlation between DNA methylation status and expression level. Together, our findings characterize the role of epigenetic changes in the regulation of miRNA transcription and create a repository of disease-specific promoter regions that may provide additional insights into the pathogenesis of CLL. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710432     DOI: 10.1158/0008-5472.CAN-12-0803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Noncoding RNA and colorectal cancer: its epigenetic role.

Authors:  Yoshiaki Kita; Keiichi Yonemori; Yusaku Osako; Kenji Baba; Shinichiro Mori; Kosei Maemura; Shoji Natsugoe
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

Review 2.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Romain Guièze; Catherine J Wu
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 3.  MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.

Authors:  K Musilova; M Mraz
Journal:  Leukemia       Date:  2014-12-26       Impact factor: 11.528

Review 4.  Molecular pathogenesis of CLL and its evolution.

Authors:  David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

Review 5.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

Review 6.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

Review 7.  Epigenetic medicine and fetal alcohol spectrum disorders.

Authors:  Marisol Resendiz; Yuanyuan Chen; Nail C Oztürk; Feng C Zhou
Journal:  Epigenomics       Date:  2013-02       Impact factor: 4.778

Review 8.  Evolving understanding of the CLL genome.

Authors:  Michaela Gruber; Catherine J Wu
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

9.  Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; George Calin; David Harris; Ping Li; Zhiming Liu; Michael J Keating; Zeev Estrov
Journal:  J Vis Exp       Date:  2016-06-15       Impact factor: 1.355

10.  Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma.

Authors:  Benjamin Goeppert; Christina Ernst; Constance Baer; Stephanie Roessler; Marcus Renner; Arianeb Mehrabi; Mohammadreza Hafezi; Anita Pathil; Arne Warth; Albrecht Stenzinger; Wilko Weichert; Marion Bähr; Rainer Will; Peter Schirmacher; Christoph Plass; Dieter Weichenhan
Journal:  Epigenetics       Date:  2016-09-03       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.